Investors Presentation
Cadila Healthcare Ltd has submitted to BSE a copy of Presentation, which the Company's Chairman and Managing Director proposed to present to the Investors in U.S.A. during his visit at U.S.A. in this month to bring to the notice of members of exchange and investors at large. Zydus receives tentative approval for Glipizide ER tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 16, 2014, titled "Zydus receives tentative approval for Glipizide ER tablets" Zydus and Gilead Enter into a Generic Licensing Agreement to manufacture breakthrough treatment for Hepatitis C
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 15, 2014 titled "Zydus and Gilead Enter into a Generic Licensing Agreement to manufacture breakthrough treatment for Hepatitis C". Zydus receives final approval for Telmisartan Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 29, 2014 titled "Zydus receives final approval for Telmisartan Tablets". Zydus receives final approval for Acyclovir Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 20, 2014 titled "Zydus receives final approval for Acyclovir Tablets". Investor Presentation
Cadila Healthcare Ltd has submitted to BSE a copy of Investor Presentation. Updates on Outcome of AGM
Cadila Healthcare Ltd has submitted to BSE a copy of proceedings of the 19th Annual General Meeting of the members of the Company held on July 30, 2014. Zydus receives final approval for Potassium Citrate ER Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 07, 2014, titled "Zydus receives final approval for Potassium Citrate ER Tablets". Disclosure of Voting results of AGM (Clause 35A)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results at the 19th Annual General Meeting (AGM) of the Company held on July 30, 2014, under Clause 35A. Limited Review for June 30, 2014
Cadila Healthcare Ltd has submitted to BSE a Copy of the Limited Review Report for the period ended June 30, 2014.